Mr. Hans E. Bishop is a Chief Executive Officer & Director at GRAIL, Inc., a Chairman at Sana Biotechnology, Inc., an Independent Director at Agilent Technologies, Inc. and a President & Director at X-Body, Inc. He is on the Board of Directors at GRAIL, Inc., JW (Cayman) Therapeutics Co. Ltd., Agilent Technologies, Inc., JW Biotechnology (Shanghai) Co. Ltd., JW Therapeutics (Shanghai) Co., Ltd., Lyell Immunopharma, Inc. and X-Body, Inc. Mr. Bishop was previously employed as a President, Chief Executive Officer & Director by Juno Therapeutics, Inc., an Independent Director by Avanir Pharmaceuticals, Inc., a Chief Operating Officer by PhotoThera, Inc., an Executive Chairman by Lion Biotechnologies, Inc., a President-Specialty Medicine Business by Bayer HealthCare Pharmaceuticals, Inc., a Senior Vice President-Global Commercial Operations by Chiron Corp., a Chief Operating Officer & Executive Vice President by Dendreon Pharmaceuticals, Inc., a Vice President & General Manager by European Biopharmaceutical Enterprises, a Principal by Glaxo Wellcome Plc, a Principal by GlaxoSmithKline LLC, and an Executive-in-Residence by Warburg Pincus LLC. He also served on the board at Celgene Corp. He received his undergraduate degree from Brunel University.